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Abstract
Chronic kidney disease (CKD) has a prevalence of approximately 10% in adult popula-
tions. CKD can progress to end-stage renal disease (ESRD) and this is usually fatal unless
some form of renal replacement therapy (chronic dialysis or renal transplantation) is pro-
vided. There is an inherited predisposition to CKD with several genetic risk markers now
identified. The UMOD gene has been associated with CKD of varying aetiologies. An
AmpliSeq next generation sequencing panel was developed to facilitate comprehensive
sequencing of the UMOD gene, covering exonic and regulatory regions. SNPs and CpG
sites in the genomic region encompassing UMOD were evaluated for association with
CKD in two studies; the UK Wellcome Trust Case-Control 3 Renal Transplant Dysfunction
Study (n = 1088) and UK-ROI GENIE GWAS (n = 1726). A technological comparison of
two Ion Torrent machines revealed 100% allele call concordance between S5 XL™ and
PGM™machines. One SNP (rs183962941), located in a non-coding region of UMOD,
was nominally associated with ESRD (p = 0.008). No association was identified between
UMOD variants and estimated glomerular filtration rate. Analysis of methylation data for
over 480,000 CpG sites revealed differential methylation patterns within UMOD, the most
significant of these was cg03140788 p = 3.7 x 10−10.
Introduction
Chronic kidney disease (CKD) is defined by sustained and often progressive decrease in renal
function (over months to years) which is generally irreversible. Renal function is most com-
monly measured by analysis of the serum creatinine concentration and then calculating an
estimated glomerular filtration rate (eGFR) using formulae based on the individual’s age, gen-
der, ethnicity and serum creatinine value [1]. Initially, CKD is typically asymptomatic and this
can mean that diagnosis is delayed and CKD has progressed further before it is recognised [2].
With earlier diagnosis and effective management, CKD progression may be slowed or even
halted [3]. CKD affects approximately 10% of adults however the prevalence in older age
groups is much higher [4], and CKD is strongly associated with cardiovascular disease
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(cardiovascular events and hospitalisations) and premature mortality [5]. Individuals with
CKD can progress to end-stage renal disease (ESRD), prompting the need for renal replace-
ment therapies, such as chronic dialysis or renal transplantation. Treatments for CKD and
ESRD represent a substantial socio-economic burden [6,7]. It is therefore important to identify
earlier biological risk markers for CKD prediction as well as to highlight potential therapeutic
targets.
Although there is evidence for a genetic predisposition to CKD, the risk alleles identified by
genome-wide association studies (GWAS) are considered to contribute only a small propor-
tion of overall complex disease risk [8,9,10,11,12]. CKD may be secondary to disorders such as
diabetes, hypertension and glomerulonephritis [13,14,15,16]. Of interest, not all persons with
diabetes, hypertension or glomerulonephritis will develop progressive CKD prompting inves-
tigation of genetic variants and epigenetic features which are associated with susceptibility to
kidney disease or “protection” from developing this complication [17,18].
The UMOD gene encodes uromodulin protein (UMOD) that is synthesized solely in the
epithelial cells of the thick ascending loop of Henle within the kidney. The role of UMOD in
normal kidney function is incompletely understood, however, mutations of the UMOD gene
are associated with autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD)
which as previously been known as familial juvenile hyperuricaemic nephropathy (FJHN) and
medullary cystic kidney disease (MCKD2), also known as UMOD-associated kidney diseases
[19,20,21,22,23]. UMOD variants have also been identified as possible risk markers for more
complex renal phenotypes such as CKD [24,25,26,27,28,29]. UMOD risk variants are associ-
ated with increased UMOD expression in vitro and in vivo [25]. For example, Olden and col-
leagues conducted meta-analysis of uromodulin levels in urine, highlighting SNPs in an LD
block around the UMOD promoter, where the G allele of rs12917707 was consistently associ-
ated with decreased eGFR and up to a 2-fold increase in urinary excretion of uromodulin in a
dose-dependent manner [28]. However, despite adequate power to identify a statistically sig-
nificant association with variants in the UMOD gene, only a few genome-wide association
studies for common renal phenotypes report UMOD as a top-ranked loci, suggesting associa-
tions may be restricted to particular population-specific phenotypes. Associations with ageing
and age-related diseases such as diabetes and hypertension have also been suggested [30,31].
UMOD may have several “reno-protective” properties. The protein can form a gel-like per-
meability barrier in the nephron, possibly aiding with chemical concentration gradient main-
tenance [32]. The non-specific, carbohydrate structure of UMOD also allows it to bind and
neutralize many molecules including urinary tract infection (UTI) causing bacteria and kidney
stone forming calcium crystals [33,34]. Furthermore, UMOD may have a role in triggering an
inflammatory response when the nephron has been damaged, thus recruiting immune cells
[35] whilst, on the other hand, basal levels of UMOD may confer a protective effect in the
event of acute ischaemic renal injury by decreasing inflammation [36]. Prolonged inflamma-
tion can trigger the development of progressive tissue fibrosis. This is in part mediated by up-
regulation of transforming growth factor-beta (TGF-β) and recruitment of fibroblasts with
resulting expansion of extracellular matrix (ECM) [37]. This progressive fibrotic process
within the kidney is associated with pathological features such as glomerular sclerosis and
tubulo-interstitial fibrosis which are correlated with clinical indicators of progressive CKD e.g.
increased proteinuria and decreased eGFR.
UMOD is therefore an attractive biological candidate gene for both the development and
progression of kidney disease. Previous studies on UMOD have examined selected exonic and
upstream regions for variants that might be associated with CKD and eGFR. We have devel-
oped a next generation sequencing (NGS) panel that covers all coding and regulatory regions,
within 2 kb upstream and downstream of UMOD. Published data was also reviewed and
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association evaluated between UMOD SNPs and ESRD. Additionally, DNA methylation data
for the UMOD gene, were analysed for association with CKD.
Methods
This study had full ethical approval from Queens University Belfast and the Office of Research
Ethics Northern Ireland. PubMed was searched (search terms: UMOD, Uromodulin, Tamm-
Horsfall protein, kidney disease, renal disease, Chronic Kidney Disease) to retrieve all publica-
tions relevant to UMOD SNPs and methylation data for any form of kidney disease (last
accessed [10 September 2015]).
Sequencing samples
Existing high quality DNA was used for this study; DNA was originally extracted using the
salting-out approach. For discovery of tag SNPs, 45 samples (23 transplant recipients with
ESRD and 22 matched kidney donors with no known renal disease) were sequenced on an Ion
Torrent Personal Genome Machine (PGM™) and 46 samples (23 transplant recipients with
ESRD and 23 matched kidney donors with no known renal disease, including the 45 samples
previously sequenced on the PGM) independently sequenced on the Ion Torrent 5S XL™ (Fig
1). This provided>95% power to detect all polymorphisms with minor allele frequency greater
than 5%. All individuals were Caucasian and from the UK.
AmpliSeq next generation sequencing panel design
Using http://www.ampliseq.com, a custom next generation sequencing panel was designed to
sequence 23,928 bp, including 2 kb both upstream and downstream, of UMOD on chromo-
some 16p12.3. The design went through several iterations before achieving maximal coverage
that was cost-effective.
Ampliseq library preparation and NGS of UMOD gene
DNA libraries were prepared according to the Ampliseq Library Preparation Kit 2.0—96Lv
(Thermo Fisher, San Diego, USA, MAN0006735) standard protocol using 20 ng of input
DNA, with samples barcoded using Ion Xpress Barcodes 1–96 (Thermo Fisher). Prepared
libraries were diluted to 26 pM using MilliQ water and combined into four samples pools, for
sequencing on four 318 chips. Twenty-five microliters of each sample pool was enriched using
a One-Touch Two (OT2) machine and automated enrichment system (Thermo Fisher) with
the Ion PGM™ Template OT2 400 Kit (Thermo Fisher) to prepare Template-positive Ion
Sphere Particles. Enriched products were prepared for sequencing using the Ion Personal
Genome Machine™ (PGM) Hi-Q Sequencing Kit and run on the Personal Genome Machine
using the Ion 318 chip v2 (Thermo Fisher, MAN0009816). In parallel, libraries for each sample
were diluted to 70 pM and loaded onto an Ion Chef for sequencing on an Ion Torrent S5 XL™
using an Ion 530 chip (Thermo Fisher, MAN0010851) (Fig 1).
Bioinformatic analysis for SNPs
Aligned BAM files from the PGM server was reformatted with SNP files generated and vali-
dated using PLINK [38], before using HaploView [39] software to assess the level of linkage
disequilibrium to discern tag SNPs which could be used for optimised association analysis. Ion
Torrent suite software version 4.6 aligned reads against the designed. BED file associated with
the hg19 reference genome; data freely available from the authors on request. Using PARTEK
genomics suite, data was mapped to hg19 and dbSNP138, filtered for log odds ratio300 and
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total coverage at locus20 to ensure reliable results, then annotated with rs# unique identifiers
(if available) and functional effects. For the association analysis we used genome-wide geno-
typing information from two studies; the UK Wellcome Trust Case-Control 3 Renal Trans-
plant Dysfunction Study (n = 1088; Affymetrix 6.0 array) comparing renal transplant
recipients with ESRD to their matched donors with no kidney disease, and UK-ROI GENIE
GWAS (n = 1726; Illumina OmniQuad array with data imputed to 1000 genomes) for controls
with type 1 diabetes and no kidney disease compared to individuals with type 1 diabetes and
kidney disease progressed to ESRD. PLINK [38] whole genome data analysis toolset was uti-
lised to extract existing GWAS data for all SNPs between the first and last flanking SNPs from
PARTEK analysis (rs9935655 to rs13333226 for Wellcome Trust data and rs4238595 and
rs4293393 for GENIE data), within the GWAS datasets. We also conducted new association
analysis using eGFR for non-ESRD samples in the UK-ROI GENIE collection. Characteristics
of samples analysed in this study are presented in S1 Table. Nominal significance for associa-
tion was set at p-value <0.05.
450K human methylation data analysis
Quantitative methylation data was previously generated using the Infinium Human Methyla-
tion 450K BeadChip (Illumina Inc.) according to manufacturer’s instructions for 255 cases
with CKD and compared to 152 controls without kidney disease [17]. Stringent quality control
was followed and adjustment for multiple testing applied to determine association between
methylation patterns and CKD and methylation data extracted for UMOD, UMODL1 and
UMODL1-AS1 genes.
Results
Next generation sequencing
Variants within the UMOD gene were determined for a total for 45 individuals; 23 kidney
transplant recipients with ESRD, and 22 matching donors with no known kidney disease.
Donor age ranged from 6–65 yrs and recipient age ranged from 11–65 yrs. Slightly more
females were present in the recipient group compared to the donor group (seven and 12
respectively).
The final AmpliSeq panel design employed 89 amplicons (125–375 bp) to cover 96.4% of
the entire UMOD gene, starting at chromosome 16 position 20342322 and finishing at position
20366250 and including 100% coverage of exons. This panel covers all mutations currently
screened by the UK Genetic Testing Network (ukgtn.nhs.uk) or published (Fig 1). An average
of 445,650 mapped reads per sample was observed using the PGM™ (range 237,240–912,642
reads) of which >97% were on target, providing a mean depth of 2,052. Two primer pools
were used to ensure that overlapping amplicons would optimally multiplex (45 amplicons in
pool 1 and 44 amplicons in pool 2) (Fig 2).
Fig 1. Ampliseq design. The UMOD gene region plus 2 kb upstream and downstream is highlighted by the
blue line, coverage by Ampliseq amplicons is shown in green and regions not covered by the optimised assay
design is shown in red. The structure of UMOD from RefSeq genes is represented in dark blue.
https://doi.org/10.1371/journal.pone.0178321.g001
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During quality control, results from two amplicons were removed as they did not meet the
minimum required reads (AMPL7158733025 failed with an average of 42 reads per sample;
AMPL7158732941 performed poorly with an average of 92 reads per sample) from the PGM
data; following removal, an average of 2,498 reads per amplicon was observed.
In total we found 119 genetic variants within our population of 23 cases with ESRD
and 22 controls without renal disease; 29 of these were insertions, deletions or multiallelic
polymorphisms (S2 Table). Genotype completion obtained for most variants was 100%;
one variant (20363262) showed 91% genotype completion. Of the remaining 90 SNPs, 60
were observed with minor allele frequency greater than 5% (S1 Fig). Using the tagger option
in HaploView revealed that 20 SNPs, in 21 tests, captured 100% of the alleles at r2>0.8
(mean r2 = 0.97) and are thus sufficient for association analysis in larger cohorts (Figs 3, 4
and 5).
Fig 2. Coverage by amplicons. Sequence heat map from Partek Genomics Suite 6.6 showing
complementary sequence coverage by pool 1 (P1) and pool 2 (P2) amplicons for pooled DNA. Areas not
covered by either pool are highlighted in red.
https://doi.org/10.1371/journal.pone.0178321.g002
Fig 3. Linkage disequilibrium plot using D’ confidence intervals. Linkage disequilibrium plot for all SNPs with minor allele frequency
>5% and in Hardy-Weinberg Equilibrium. Colour scheme for D’ confidence interval plot: Strong evidence of LD (dark grey), Strong evidence
of recombination (white), Uninformative (light grey).
https://doi.org/10.1371/journal.pone.0178321.g003
Next generation sequencing panel for UMOD
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Initial PARTEK analysis revealed a total of 3,317 differences from the reference sequence
across all samples (n = 45) where log odds ratio5. 116 unique variants were discovered in
the UMOD region with log odds ratio 300 and at least 20 reads of which 78 had rs identifiers
in dbSNP build 138. The functional effect of SNPs differs depending on which UMOD tran-
script is considered; for example, one variant at 20352618 (rs55772253) in our discovery
cohort exerted a non-synonymous effect on different exons depending on the transcript
(Table 1; Fig 6).
An average of 195,205 mapped reads per sample was observed using the S5 XL™ (range
100,081–258,626 reads) of which >98% were on target, providing a mean depth of 965. Com-
parative results obtained from 318 and 530 chips (Fig 7) confirm both PGM and S5 XL are
suitable for this analysis, with the choice of machine optimally guided by the number of sam-
ples to be sequenced.
Fig 4. Linkage disequilibrium plot using r2. Linkage disequilibrium plot for all SNPs with minor allele frequency >5% and in Hardy-
Weinberg Equilibrium. Colour scheme for r2 plot as follows: r2 = 0 (white), 0 < r2 < 1 (shades of grey), r2 = 1 (black).
https://doi.org/10.1371/journal.pone.0178321.g004
Fig 5. Haplotype blocks. Haplotype blocks with population frequencies displayed next to each haplotype.
Lines represent the most common crossings between block (thicker lines are more common) beneath which
the value of multiallelic D’ is shown, measuring the level of linkage disequilibrium (LD) between blocks.
Greater recombination is denoted by a value closer to zero.
https://doi.org/10.1371/journal.pone.0178321.g005
Next generation sequencing panel for UMOD
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Association analysis
Ninety-two SNPs were extracted from the UK/ROI GEnetics of Nephropathy—an Interna-
tional Effort GWAS study (GENIE) and seven SNPs were extracted from the Wellcome Trust
Case-Control 3 Renal Transplant Dysfunction Study (WTCCC3-RTD) study (two of these
Table 1. Chromosome location and alleles associated with multiple transcripts and associated gene locations for non-synonymous SNP
rs55772253.
Chromosome Position Reference
allele
Alternate
allele
Transcript Gene
Section
Functional
Effect
Nucleotide
Change
Amino Acid
change
Chr 16 20352618 C A NM_001008389
NM_003361
Exon 7
Exon 7
Missense c.1372G>T V458L
Chr 16 20352618 C A NM_001278614 Exon 8 Missense c.1471G>T V491L
https://doi.org/10.1371/journal.pone.0178321.t001
Fig 6. UMOD transcripts. Three UMOD transcripts (3’-5’) from NCBI gene website [last accessed: 17/10/
2015]. Green blocks indicate the position of exons on the sequence with arrows denoting the direction of
expression.
https://doi.org/10.1371/journal.pone.0178321.g006
Fig 7. Comparison of suitability of PGM and S5XL next generation sequencers for analysis of UMOD.
https://doi.org/10.1371/journal.pone.0178321.g007
Next generation sequencing panel for UMOD
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SNPs were not found in GENIE) (S3 Table). Only one SNP extracted from the GENIE study,
was nominally significantly associated with ESRD (rs183962941: p = 0.008). This SNP was not
in linkage disequilibrium (LD) with any previously reported associated variants. Four other
variants, extracted from the GENIE study, showed a trend towards significance, (rs191101580,
rs187087030, rs8060932, rs8062123), and rs8060932 is in LD with another SNP (rs4238595)
associated with FJHN [21]. Our study did not reveal any association with eGFR for non-ESRD
samples with or without diabetes. No SNPs in the WTCCC3-RTD study revealed any signifi-
cant association with ESRD or eGFR.
Methylation data analysis
Methylation status was determined for 485,577 CpG sites in a total of 407 individuals. Signifi-
cant cg sites were extracted from the large dataset for UMOD, UMOL1 and UMODL1-AS1. Fol-
lowing stringent quality control and analysis differential methylation of three cg sites was
observed in UMOD revealing cg03140788 as the most significant with a p-value of 3.7x10-10
(Table 2). Two related genes that are also expressed in the kidney; UMODL1 and UMO-
DL1-AS1, were explored, revealing eight associated CpG sites, with genome wide significance;
Pmax = 2.9x10
-32 (cg16624482) was the most significant for non-diabetic ESRD. A list of SNPs
that could influence probe binding and thus affect DNA methylation is provided in S4 Table.
Discussion
This study aimed to develop a next generation sequencing (NGS) assay for the detection of
variants in the UMOD gene, covering both coding and non-coding regions. A cost-effective
approach for targeted sequencing or comprehensive genotyping of individuals and larger pop-
ulation-based cohorts was developed using20 ng of input DNA (Fig 8).
We observed one SNP, rs183962941 nominally associated with ESRD (p = 0.008), which
has not been previously reported and was not shown to be in LD with any other variant using
the SNP Annotation and Proxy Search (SNAP—Broad Institute [last accessed: 14 September
2015] [40]). Located in the intronic region between exons 6 and 7 of UMOD, the potential
function of rs183962941 remains to be determined; searching the Blood eQTL browser [41],
the GTEx Portal [42], or HaploReg v4 [43] does not reveal functional associations with this
SNP, however it should be noted this SNP is not present on common Illumina or Affymetrix
Table 2. Showing sites within UMOD, UMODL1 and UMODL1-AS1 that are significantly associated with CKD.
Symbol Description CpG site Features Adj. P-value
UMOD Uromodulin cg03140788 Body; CpG Island 3.7 x 10−10
cg07817806 3’UTR 4.4 x 10−6
cg06861044 Body; CpG Island 6.6 x 10−5
UMODL1 Uromodulin-Like 1 cg16624482 Body; S_Shore 2.90 x 10−32
cg21935742 TSS200 8.10 x 10−31
cg09727148 3’UTR 2.10 x 10−28
cg23931796 TSS200 4.70 x 10−27
cg00785029 Body 3.20 x 10−8
cg03643948 Body; Island 8.90 x 10−12
cg01542693 Body; S_Shore 2.40 x 10−9
cg03240473 Body; Island 1.50 x 10−12
UMODL1-AS1 Uromodulin-Like 1- Anti-Sense 1 cg01542693 TSS200 2.40 x 10−9
cg03240473 Body; Island 1.50 x 10−12
https://doi.org/10.1371/journal.pone.0178321.t002
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genotyping arrays, HapMap CEU release 22, or 1000 genomes pilot 1 according to SNAP [40].
Of the 116 SNPs annotated in PARTEK analysis, 91 were identified within intronic and / or
potential regulatory regions, which may be important to help create a better risk profile for
kidney disease.
Four other variants were extracted from the GENIE study, which were trending towards
significance at the five percent level (rs191101580, rs187087030, rs8060932, rs8062123); one of
these (rs8060932; p = 0.08) was shown to be in LD with another SNP, rs4238595 (r2 = 0.89),
associated with FJHN [21]. rs13333226 has been previously reported to be associated with
reduced urinary uromodulin excretion as well as lower risk of hypertension and cardiovascular
disease [13], however there was no evidence of association in this cohort. rs13333226 is also in
LD with the most common SNP for UMOD (rs12917707), which has been reported to be asso-
ciated with CKD, eGFR and ESRD [8,9,11,26,28].
Two non-synonymous SNPs were identified from a variant at position 20352618
(rs55772253), resulting in an amino acid change V458L or V491L depending on the UMOD
transcript. V458L was previously reported by Kottgen et al. [24] who suggested it was associ-
ated with decreased eGFR and concentration of uromodulin; this SNP is ‘probably damaging’
(score 0.998) according to prediction software SIFT [44] and PolyPhen-2 [45].
The significant differential methylation pattern in UMOD (cg03140788 p = 3.7 x 10−10) was
detected in a gene body CpG island (CGI). Jones et al. [46] suggest that methylation of a gene
body CGI may be a method of controlling transcription of a gene that has two promoters
(alternative promoter usage) by stopping transcription from this site while still allowing tran-
scription and elongation from the earlier promoter.
Fig 8. Sequencing workflow. Workflow for Ion Torrent PGM and S5 XL showing hands on time and total
time for template preparation and sequencing.
https://doi.org/10.1371/journal.pone.0178321.g008
Next generation sequencing panel for UMOD
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Association was also identified in UMODL1 and UMODL1-AS1. UMODL1 was first charac-
terised in 2004, but there has been little work published on this gene, with only 11 articles in
PubMed returned from a search of ‘UMODL1’, and one returned from a search of ‘UMODL1
and kidney’ (February 2017). This gene is expressed in the kidney [47] and genome-wide asso-
ciation analysis of 3,851 individuals revealed association with UMODL1 and CKD [48]. UMO-
DL1-AS1 is a long non-coding RNA, which has been little studied to date, but has potential to
provide prognostic information for CKD.
We observed 100% SNP concordance between the S5 XL™ and PGM™ in SNPs with a quality
score greater than 100. A visual review of highlighted differences between TorrentSuite-based
SNP calling from the two sequencers revealed a microsatellite and homopolymer region (eight
A/T) which generated experimental artefacts. Both PGM™ and S5 XL™ are ideally suited for tar-
geted SNP and indel detection, while S5 XL™ represents a significant cost saving in terms of
labour and consumables compared to using PGM™.
This study combines genetic and epigenetic investigations to improve understanding of the
genetic architecture of the UMOD gene region. Strengths of the study included its significant
power to identify 95% of variants with MAF >5% in 45 carefully phenotyped individuals, as
well as the replication on the S5 XL™ sequencer and 100% concordance of SNPs between both
next generation sequencers. However, tens of thousands of individuals will be required to eval-
uate rare variants in this gene to provide adequate power to identify significant associations
for rare SNPs. A potential limitation to this study was that all samples were Caucasian and so
variants that might be present within other ethnicities were not assessed.
In summary, there is sufficient evidence to suggest variants at the UMOD locus are associ-
ated with Mendelian and more common complex CKD aetiologies; larger, more comprehen-
sive studies are warranted. Many SNPs that have been significantly associated with CKD are
only nominally associated with ESRD if at all, perhaps suggesting different roles of action or
the need for more carefully phenotyped cohorts. Large observational CKD studies such as
GEnetics of Nephropathy: an International Effort (GENIE) [49], Chronic Renal Insufficiency
Cohort (CRIC) [50] and German Chronic Kidney Disease Study (GCKD) [51] will allow more
insight into the development of ESRD, and hopefully lead to the identification of a more com-
prehensive risk profile for both CKD and ESRD.
Supporting information
S1 Table. Characteristics of samples analysed in this study.
(PDF)
S2 Table. SNPs uniquely identified from sequencing data.
(PDF)
S3 Table. List of SNPs uniquely extracted either in the UK/ROI GEnetics of Nephrology an
International Effort cohort or Wellcome Trust Case- Control 3 Renal Transplant Dysfunc-
tion Study cohort.
(PDF)
S4 Table. SNPs that could influence probe binding for certain cg sites in UMOD and
UMODL1. Highlighted in bold font are cg sites that had significant p-values.
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S1 Fig. SNPs depicted as blue lines across the gene structure with exons noted.
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